📰 Conditional Marketing News
Conditional Marketing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Conditional Marketing. Real-time updates on events, politics, business and more.
September 25, 2023
 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...
September 25, 2023
TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...
September 25, 2023
Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...
July 21, 2023
SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced the European Medicine Agencys Committee for...
May 12, 2023
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2023, as well as key clinical and corporate developments. Clinical and Corporate Developments include: In... | June 14, 2023
July 21, 2022
- Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication - - Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 - NEWTON, Mass.andFLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharm...
June 16, 2022
Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm,' today announced it entered
May 20, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...
May 20, 2022
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI),
May 1, 2022
21st Austria weekly - Andritz Agrana Valneva 25/04/2022 [pic1]Andritz: International technology group Andritz has received an order from Papierfabriek Doetinchem Netherlands to upgrade the wet sections of its PM1 and PM3 special paper machines. The start-ups are scheduled for 2022. aim investment is improve quality provide basis a possible capacity increase. will deliver ModuScreen HB dilution headbox screens PrimeFlow AT headboxes with PrimeProfiler F control pumps both machines.Andritz: